Policy & Regulation

This report and accompanying discussion by ASPE and NORC highlights the claims data limitations identified during the COVID-19 Public Health Emergency Health (PHE) and provides considerations to address these limitations. The report identifies that limitations related to claims data were existing issues, exacerbated by, but not unique to, the COVID-19 PHE.

Evidence Gap Map: Research Report and Overview

The cornerstone of a well-functioning market is competition. President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” identified a lack of competition as a key driver for problems across economic sectors.

State and Local Estimates of the Uninsured Population in the U.S. Using the Census Bureau’s 2022 American Community SurveyMethodological Description

The U.S. Department of Health and Human Services (HHS) envisions a future in which everyone, regardless of their social circumstances, has access to aligned health and social care systems that achieve equitable outcomes through high-quality, affordable, person-centered care. This Call to Action complements the companion U.S.

ASPE, in partnership with the Administration for Community Living, commissioned the RAND Corporation to better understand existing approaches to coordinating health and social care services through backbone organizations, with a focus on one particular model, community care hubs (Hubs).

Stakeholders, researchers, and policymakers have identified varying nursing home ownership structures and ownership transactions as potentially influencing the quality of care delivered to vulnerable residents.

According to the most recent National Health Interview Survey data, the national uninsured rate in the second quarter of 2023 was 7.2 percent, unchanged statistically from the first quarter of 2023.

Drug manufacturers may change the list prices of their drugs at any time after launch. Over the period from January 2022 to January 2023, more than 4,200 drug products had price increases, of which 46 percent were larger than the rate of inflation. The average drug price increase over the course of the period was 15.2 percent, which translates to $590 per drug product.

The Inflation Reduction Act (IRA) is helping people with Medicare afford their medications, including the 2.1 million Asian, 5.8 million Black, and 5.3 million Latino Part D enrollees. These fact sheets review existing research to present the projected impacts of key IRA Medicare drug-related provisions for these populations.